[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595180":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":67,"collaborators":19,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":19,"enrollmentInfo":78,"targetDuration":19,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":91,"whyStopped":19,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Centre Henri Becquerel","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ex-vivo Organoid culture","EXPERIMENTAL","ex-vivo organoid culture after tumor resection",[13],"Other: Ex-vivo organoid culture",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Ex-vivo organoid culture","ex-vivo organoid cultures composed of tumor cells within their microenvironment (glioblastoma organoid - GBO) and intra- and peri-tumoral blood vessels (blood vessel organoid - BVO), derived from perioperative samples obtained during complete or partial surgical resection",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Maxime Fontanille, MD,PhD","CONTACT","+33276673091","maxime.fontanilles@chb.unicancer.fr",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Doriane Richard, PhD","+33232082985","doriane.richard@chb.unicancer.fr",[31,47,57],{"facility":32,"status":19,"city":33,"state":19,"zip":19,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Groupe Hospitalier du Havre","Le Havre","France","FR",{"type":37,"coordinates":38},"Point",[39,40],0.10785,49.49346,{"lat":40,"lon":39},[43],{"name":44,"role":23,"phone":45,"phoneExt":19,"email":46},"Marine Lacaud","+332 32 73 32 32","marine.lacaud@ch-havre.fr",{"facility":5,"status":19,"city":48,"state":19,"zip":19,"country":34,"countryCode":35,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Rouen",{"type":37,"coordinates":50},[51,52],1.09932,49.44313,{"lat":52,"lon":51},[55],{"name":56,"role":23,"phone":24,"phoneExt":19,"email":25},"Maxime Fontanilles",{"facility":58,"status":19,"city":48,"state":19,"zip":19,"country":34,"countryCode":35,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"CHU Rouen",{"type":37,"coordinates":60},[51,52],{"lat":52,"lon":51},[63],{"name":64,"role":23,"phone":65,"phoneExt":19,"email":66},"Olivier Langlois","+33232888042","olivier.langlois@chu-rouen.fr",{"type":68,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100595180","feasibility-of-organoids-in-routine-clinical-practice-for-molecular-analysis-of-the-gliovascular-niche-in-patients-with-primary-brain-tumors-100595180",false,"NCT07029100","Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With Primary Brain Tumors.","ORGA-GLIO","Inclusion Criteria:\n\n* Patient, male or female, adult (age ≥ 18 years),\n* Suspected of having a high-grade glioma based on preoperative multimodal MRI,\n* With an indication for tumor resection surgery,\n* And in a clinical condition suitable to undergo adjuvant treatment consisting of radiotherapy (normo- or hypo-fractionated) combined with temozolomide, with or without low-frequency electric fields (Tumor-Treating Fields®).\n\nExclusion Criteria:\n\n* Current tumor pathology or history of tumor pathology in remission for less than 2 years\n* Pregnant or breastfeeding women,\n* Patients unable to understand the study for any reason or unable to comply with trial requirements (language barriers, psychological or geographical issues, etc.).","ALL","18 Years",{"count":79,"type":80},30,"ESTIMATED","INTERVENTIONAL",[83],"NA","The main goal of ORGA-GLIO trial is to establish the feasibility in routine clinical practice of ex-vivo organoid cultures composed of tumor cells within their microenvironment (glioblastoma organoid - GBO) and intra- and peri-tumoral blood vessels (blood vessel organoid - BVO), derived from perioperative samples obtained during complete or partial surgical resection in patients with newly diagnosed glioblastoma.",[86],"Glioblastoma",[88,89,90],"glioblastoma","organoide","molecular analysis","NOT_YET_RECRUITING","2025-06-18",{"date":94,"type":95},"2025-06-19","ACTUAL",{"date":97,"type":80},"2025-07-01",{"date":99,"type":80},"2029-07-01",{"name":5,"class":6},3]